Individuals of South Asian descent exhibit significantly higher central adiposity and insulin resistance at a much lower Body Mass Index compared to Caucasian populations. The WHO established the Asia-Pacific cutoff to trigger earlier screening for Type 2 Diabetes Mellitus and ASCVD. Under these criteria, an Asian patient with a BMI of 23.5 is considered clinically Overweight.
2. Pharmacological Dosing Weights
Adipose tissue contains less water than lean muscle. Therefore, highly hydrophilic drugs (like Aminoglycosides or Vancomycin) do not distribute well into fat.
• If Actual Weight is normal, dose via Actual or Ideal Body Weight.
• If the patient is obese (>120% of IBW), calculating doses on Actual Weight will cause fatal toxicity. You must synthesise the Adjusted Body Weight (ABW), which applies a 0.4 correction factor for the extra adipose volume.
The Devine IBW formula was designed for patients over 5 feet (60 inches / 152.4 cm) tall. It loses mathematical integrity in severe short stature. Furthermore, BMI cannot distinguish between massive fluid overload (e.g., anasarca in decompensated cirrhosis), heavy musculature (bodybuilders), or true adiposity. Use clinical gestalt.
| Classification | WHO Standard (kg/m²) | Asia-Pacific (kg/m²) |
|---|---|---|
| Underweight | < 18.5 | < 18.5 |
| Normal Range | 18.5 – 24.9 | 18.5 – 22.9 |
| Overweight | 25.0 – 29.9 | 23.0 – 24.9 |
| Obese | ≥ 30.0 | ≥ 25.0 |
Algorithm References & Evidence Base
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163.
- Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
- Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655.
Access all evidence-based algorithms, prognostic matrices, and pharmacotherapeutic pathways.
← View All Clinical Modules
